Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease

Oskar Hansson, Nicholas Cullen, Henrik Zetterberg, Kaj Blennow, Niklas Mattsson-Carlgren, Alzheimer's Disease Neuroimaging Initiative

Research output: Contribution to journalArticlepeer-review

Abstract

We examined if plasma phosphorylated tau is associated with neurodegeneration in Alzheimer’s disease. We investigated 372 cognitively unimpaired participants, 554 mild cognitive impairment patients, and 141 Alzheimer’s disease dementia patients. Tau phosphorylated at threonine 181, regional cortical thickness (using magnetic resonance imaging) and hypometabolism (using fluorodeoxyglucose positron emission tomography) were measured longitudinally. High plasma tau was associated with hypometabolism and cortical atrophy at baseline and over time, and longitudinally increased tau was associated with accelerated atrophy, but these associations were only observed in Aβ-positive participants. Plasma phosphorylated tau may identify and track processes linked to neurodegeneration in Alzheimer’s disease.

Original languageEnglish
Pages (from-to)259-265
JournalAnnals of Clinical and Translational Neurology
Volume8
Issue number1
Early online date2020 Nov 29
DOIs
Publication statusPublished - 2021

Subject classification (UKÄ)

  • Neurology

Fingerprint

Dive into the research topics of 'Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease'. Together they form a unique fingerprint.

Cite this